Holen Sie sich die Stockscreener-App
4.705
2.93%
-0.165
Schlusskurs vom Vortag:
$4.87
Offen:
$4.9
24-Stunden-Volumen:
35,896
Relative Volume:
0.11
Marktkapitalisierung:
$376.93M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-169.52M
KGV:
-2.2155
EPS:
-2.1237
Netto-Cashflow:
$-147.86M
1W Leistung:
+1.66%
1M Leistung:
+11.23%
6M Leistung:
+35.84%
1J Leistung:
+29.87%
1-Tages-Spanne:
$4.71
$4.90
1-Wochen-Bereich:
$4.625
$5.035
52-Wochen-Spanne:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 284-8891
Adresse
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.71 | 372.13M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
519.88 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
661.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.55 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.88 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.82 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Refocuses Antiviral Pipeline - Kalkine Media
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR) - TradingView
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Atea completes enrollment in phase 3 hepatitis C trial By Investing.com - Investing.com Australia
Atea completes enrollment in phase 3 hepatitis C trial - Investing.com UK
Atea Pharmaceuticals Completes Patient Enrollment in Phase - GlobeNewswire
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Nigeria
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs - Stock Titan
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings - Stock Titan
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR) - Stock Titan
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards - Stock Titan
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director - Stock Titan
Atea Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Nigeria
Atea Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes - Stock Titan
Atea Pharmaceuticals (AVIR) upgraded to buy: Here's what you should know - MSN
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Institutional Confidence - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN
Atea Pharmaceuticals (AVIR) Slides 3.79%: Testing Key Support Near $4.10 Amid Ongoing VolatilitySchiff Line - dars.gov.et
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Atea Pharmaceuticals (AVIR) Rallies 1.65% as Shares Test Key Resistance Near $4.54Scalping Stock Signals - newsline.com
Atea Pharmaceuticals (AVIR) Declines 3.85% as Shares Approach Key Support LevelPCR Mean Reversion - newsline.com
AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atea Pharmaceuticals Inc-Aktie (AVIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
536,097 |
| DUNCAN BARBARA GAYLE | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Polsky Bruce | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
124,806 |
| Murphy Polly A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
121,745 |
| Adams Jerome M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Corcoran Andrea | See Remarks |
Mar 11 '26 |
Option Exercise |
1.24 |
60,000 |
74,400 |
823,576 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):